TRxADE HEALTH Inc. (MEDS)
TRxADE HEALTH Statistics
Share Statistics
TRxADE HEALTH has 1.75M shares outstanding. The number of shares has increased by 24.44% in one year.
| Shares Outstanding | 1.75M |
| Shares Change (YoY) | 24.44% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.05% |
| Shares Floating | 734.54K |
| Failed to Deliver (FTD) Shares | 1.35K |
| FTD / Avg. Volume | 1.55% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is null and the forward PE ratio is null.
| PE Ratio | null |
| Forward PE | n/a |
| PS Ratio | 0.48 |
| Forward PS | null |
| PB Ratio | 7.33 |
| P/FCF Ratio | null |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TRxADE HEALTH.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.24, with a Debt / Equity ratio of null.
| Current Ratio | 0.24 |
| Quick Ratio | 0.24 |
| Debt / Equity | null |
| Debt / EBITDA | -1.15 |
| Debt / FCF | -3.43 |
| Interest Coverage | null |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.03M |
| Profits Per Employee | $-2.23M |
| Employee Count | 8 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 5.86K |
Taxes
| Income Tax | 5.34M |
| Effective Tax Rate | -38.89% |
Stock Price Statistics
The stock price has increased by 18.04% in the last 52 weeks. The beta is 2.17, so TRxADE HEALTH's price volatility has been higher than the market average.
| Beta | 2.17 |
| 52-Week Price Change | 18.04% |
| 50-Day Moving Average | 7.29 |
| 200-Day Moving Average | 8.98 |
| Relative Strength Index (RSI) | 42.89 |
| Average Volume (20 Days) | 86.93K |
Income Statement
In the last 12 months, TRxADE HEALTH had revenue of 8.27M and earned -17.84M in profits. Earnings per share was -23.35.
| Revenue | 8.27M |
| Gross Profit | 2.6M |
| Operating Income | -7.26M |
| Net Income | -17.84M |
| EBITDA | -6.19M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -23.35 |
Balance Sheet
The company has 151.91K in cash and 7.1M in debt, giving a net cash position of -6.95M.
| Cash & Cash Equivalents | 151.91K |
| Total Debt | 7.1M |
| Net Cash | -6.95M |
| Retained Earnings | -33.25M |
| Total Assets | 14.85M |
| Working Capital | 9.17M |
Cash Flow
In the last 12 months, operating cash flow was -2.07M and capital expenditures 0, giving a free cash flow of -2.07M.
| Operating Cash Flow | -2.07M |
| Capital Expenditures | 0 |
| Free Cash Flow | -2.07M |
| FCF Per Share | -2.71 |
Margins
Gross margin is 31.41%, with operating and profit margins of -87.8% and -215.7%.
| Gross Margin | 31.41% |
| Operating Margin | -87.8% |
| Pretax Margin | -165.86% |
| Profit Margin | -215.7% |
| EBITDA Margin | n/a |
| EBIT Margin | -87.8% |
| FCF Margin | -25.07% |
Dividends & Yields
MEDS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for MEDS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jun 22, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Jun 22, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -1.99 |
| Piotroski F-Score | 3 |